A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC) (MATTERHORN)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507338-26-00

Acronym

D910GC00001

Enrollment

341

Registered

2024-01-29

Start date

2021-02-01

Completion date

Unknown

Last updated

2025-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Histologically documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (Stage II or higher per AJCC 8th edition).

Brief summary

EFS (event free survival)

Detailed description

OS (Overall Survival), pCR rate

Interventions

DRUGPLACEBO

DRUGDOCETAXEL

DRUGOXALIPLATIN

DRUGFLUOROURACIL

DRUGINFLIXIMAB

DRUGFOLINIC ACID

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

DRUGMYCOPHENOLATE MOFETIL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
EFS (event free survival)	—

Secondary

Measure	Time frame
OS (Overall Survival), pCR rate	—

Countries

Belgium, Denmark, France, Germany, Hungary, Netherlands, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026